Cansino Biologics Stock Net Income
| CASBF Stock | USD 4.47 0.00 0.00% |
As of the 5th of February, CanSino Biologics shows the Mean Deviation of 0.9511, standard deviation of 2.58, and Risk Adjusted Performance of (0.08). CanSino Biologics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm CanSino Biologics variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and kurtosis to decide if CanSino Biologics is priced correctly, providing market reflects its regular price of 4.47 per share. Given that CanSino Biologics has total risk alpha of (0.51), we suggest you to validate CanSino Biologics's prevailing market performance to make sure the company can sustain itself at a future point.
CanSino Biologics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing CanSino Biologics' valuation are provided below:CanSino Biologics does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. CanSino |
CanSino Biologics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to CanSino Biologics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of CanSino Biologics.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in CanSino Biologics on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding CanSino Biologics or generate 0.0% return on investment in CanSino Biologics over 90 days. CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China More
CanSino Biologics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure CanSino Biologics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess CanSino Biologics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 16.88 | |||
| Value At Risk | (3.60) |
CanSino Biologics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for CanSino Biologics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as CanSino Biologics' standard deviation. In reality, there are many statistical measures that can use CanSino Biologics historical prices to predict the future CanSino Biologics' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.33) | |||
| Total Risk Alpha | (0.51) | |||
| Treynor Ratio | (1.10) |
CanSino Biologics February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (1.09) | |||
| Mean Deviation | 0.9511 | |||
| Coefficient Of Variation | (840.29) | |||
| Standard Deviation | 2.58 | |||
| Variance | 6.65 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.33) | |||
| Total Risk Alpha | (0.51) | |||
| Treynor Ratio | (1.10) | |||
| Maximum Drawdown | 16.88 | |||
| Value At Risk | (3.60) | |||
| Skewness | (1.54) | |||
| Kurtosis | 16.08 |
CanSino Biologics Backtested Returns
CanSino Biologics secures Sharpe Ratio (or Efficiency) of -0.12, which signifies that the company had a -0.12 % return per unit of risk over the last 3 months. CanSino Biologics exposes seventeen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm CanSino Biologics' Standard Deviation of 2.58, mean deviation of 0.9511, and Risk Adjusted Performance of (0.08) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.29, which signifies not very significant fluctuations relative to the market. As returns on the market increase, CanSino Biologics' returns are expected to increase less than the market. However, during the bear market, the loss of holding CanSino Biologics is expected to be smaller as well. At this point, CanSino Biologics has a negative expected return of -0.34%. Please make sure to confirm CanSino Biologics' maximum drawdown, as well as the relationship between the kurtosis and day typical price , to decide if CanSino Biologics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.34 |
Below average predictability
CanSino Biologics has below average predictability. Overlapping area represents the amount of predictability between CanSino Biologics time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of CanSino Biologics price movement. The serial correlation of 0.34 indicates that nearly 34.0% of current CanSino Biologics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.34 | |
| Spearman Rank Test | 0.33 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, CanSino Biologics reported net income of 1.91 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is significantly lower than that of the firm.
CanSino Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CanSino Biologics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of CanSino Biologics could also be used in its relative valuation, which is a method of valuing CanSino Biologics by comparing valuation metrics of similar companies.CanSino Biologics is currently under evaluation in net income category among its peers.
CanSino Fundamentals
| Return On Equity | 0.0111 | |||
| Return On Asset | -0.0207 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | (0.19) % | |||
| Current Valuation | 3.58 B | |||
| Shares Outstanding | 114.78 M | |||
| Shares Owned By Insiders | 26.70 % | |||
| Shares Owned By Institutions | 38.17 % | |||
| Price To Earning | 19.25 X | |||
| Price To Book | 2.30 X | |||
| Price To Sales | 2.51 X | |||
| Revenue | 4.3 B | |||
| Gross Profit | 3 B | |||
| EBITDA | 2.05 B | |||
| Net Income | 1.91 B | |||
| Cash And Equivalents | 7 B | |||
| Cash Per Share | 28.36 X | |||
| Total Debt | 40 M | |||
| Debt To Equity | 0.26 % | |||
| Current Ratio | 2.99 X | |||
| Book Value Per Share | 29.22 X | |||
| Cash Flow From Operations | 2.05 B | |||
| Earnings Per Share | 0.59 X | |||
| Number Of Employees | 1.95 K | |||
| Beta | 0.61 | |||
| Market Capitalization | 3.15 B | |||
| Total Asset | 11.87 B | |||
| Z Score | 46.8 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 11.87 B | |||
| Last Dividend Paid | 0.8 |
About CanSino Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CanSino Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CanSino Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CanSino Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in CanSino Pink Sheet
CanSino Biologics financial ratios help investors to determine whether CanSino Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CanSino with respect to the benefits of owning CanSino Biologics security.